Editorial & Advertiser disclosure

Global Banking & Finance Review® is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Four Tips From Philippe Weiss to Keep the Madness Distractions & Mayhem to a Minimum:

Published by Gbaf News

Posted on March 18, 2017

2 min read

Last updated: January 21, 2026

Add as preferred source on Google

Graphic depicting Novo Nordisk's Ozempic diabetes drug and NAION eye disease risk - Global Banking & Finance Review — An informative graphic illustrating the link between Novo Nordisk's Ozempic and the increased risk of NAION, a rare eye disease. This image supports the article discussing recent studies and regulatory scrutiny.